Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Y Cheng, Q Wang, K Li, J Shi, Y Liu, L Wu… - British Journal of …, 2021 - nature.com
Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …
被引用次数：107 相关文章
[HTML] nih.gov

[HTML][HTML] Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Y Cheng, Q Wang, K Li, J Shi, Y Liu, L Wu… - British Journal of …, 2021 - ncbi.nlm.nih.gov
Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …

Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study.

Y Cheng, Q Wang, K Li, J Shi, Y Liu, L Wu… - British Journal of …, 2021 - europepmc.org
Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …

Anlotinib vs placebo as third-or further-line treatment for patients with small cell lung cancer: a randomised, double-blind, placebo-controlled Phase 2 study

Y Cheng, Q Wang, K Li, J Shi, Y Liu… - British journal of …, 2021 - pubmed.ncbi.nlm.nih.gov
Background This study aimed to evaluate the efficacy and safety of anlotinib as a third-line
and subsequent treatment for patients with small cell lung cancer (SCLC). Methods We …